Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a consent form agreeing to take part in the study.
• People aged 18 or older.
• People who have been diagnosed (confirmed by lab testing of tissue or cells) with a specific type of ovarian, fallopian tube, or peritoneal cancer — specifically high-grade serous or endometrioid type, or a cancer that is mainly serous or endometrioid (regardless of BRCA1 or HRD gene status).
• People whose cancer has come back or grown within 6 months after finishing platinum-based chemotherapy, or who are not able to receive platinum-based chemotherapy.
• People who have received no more than one treatment regimen since their cancer became resistant to platinum chemotherapy (note: prior treatment with a drug called Elahere does not count toward this limit).
• People who have measurable cancer visible on a CT scan or MRI taken within 4 weeks before starting the trial.
• People who are generally well enough to carry out light daily activities — rated 0 or 1 on a standard medical fitness scale (confirm with trial site).
• People who are expected to live for more than 16 weeks.
• People who have recovered from most side effects of previous surgery, radiation, or cancer treatments (side effects must have reduced to a mild level or resolved).
• People whose blood test results meet specific minimum standards for blood cell counts, liver function, kidney function, and other markers (the trial site will check these results).
• People who can provide a tumour tissue sample — either from the current relapse or, if not available, from the most recent stored sample. People previously treated with a PARP inhibitor drug must have a new biopsy unless a stored sample taken after that treatment was stopped is available.
• Women who could potentially become pregnant must have a negative blood pregnancy test before joining.
• Women who could potentially become pregnant and are sexually active must use an approved form of contraception throughout the trial and for at least six months after it ends.

Who may not be able to join:

• People whose cancer grew or spread while they were still receiving platinum-based chemotherapy (rather than after finishing it).
• People who are currently receiving other chemotherapy, antibody treatments, radiation therapy, hormonal therapy, or other experimental drugs (except medications for unrelated health conditions, such as insulin for diabetes).
• People who have another current cancer, except for early-stage cancers (Stage I or II) that the treating doctor considers fully cured.
• People with an active infection currently being treated with antibiotic medication (oral or intravenous).
• People known to be HIV positive.
• People with known active hepatitis B or C infection.
• People with significant heart or cardiovascular problems, including: a stroke within the past 12 months, a mini-stroke (TIA) within the past 12 months, a heart attack within the past 12 months, unstable chest pain (angina), moderate-to-severe heart failure, or an uncontrolled irregular heartbeat requiring medication.
• People taking other medications or who have other conditions that, in the treating doctor's opinion, would make participation unsafe or affect the study results.
• People who are unable to swallow oral medication, or who have a digestive condition (such as uncontrolled nausea, diarrhoea, vomiting, or a malabsorption disorder) that could affect how the trial drug is absorbed by the body.
• People who need urgent palliative treatment, including surgery or radiation therapy, right away.
• People who would not be able to attend regular follow-up visits for any reason — including geographic, social, psychological, or personal circumstances, or because they are in an institution such as a prison.
• People who are close colleagues, family members, or dependants of the study sponsor or the investigator running the trial.
• People who have needed more than 500ml of fluid drained from their abdomen (ascites drainage) in the two weeks before enrolment.

Important: Always verify eligibility with the trial site directly before applying.